At the news
? BULLISHIMPACT 7/10 6-K filed Jun 29, 2026 at 17:22 ET
Abivax reported positive topline results from Part 2 of the Phase 3 ABTECT maintenance trial for obefazimod in ulcerative colitis, showing clinically meaningful efficacy in refractory patients (37.2% clinical remission at 50 mg in induction non-responders) and a safety profile with malignancy rates within UC background ranges. The company remains on track for NDA submission in Q4 2026, strengthening the drug's regulatory path.
- 50 mg obefazimod achieved 37.2% clinical remission, 61.5% clinical response, 48.0% endoscopic improvement, 44.6% HEMI, and 34.5% endoscopic remission in induction non-responders at Week 44.
- Part 1 relapsers re-treated with 50 mg obefazimod achieved 45.0% clinical remission (placebo→50 mg) and 45.5% (25 mg→50 mg).
- Exposure-adjusted incidence rate (EAIR) for malignancies excluding NMSC in the integrated UC program (all active) was 0.35 per 100 PY, within the UC background range of 0.30–0.70.
- EAIR for NMSC in the integrated program (all active) was 0.59 per 100 PY, within the UC background range of 0.70–1.40.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access